{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:13:54Z","timestamp":1792113234018,"version":"4.4.0"},"reference-count":70,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK\/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be promising for CTCL treatment. This study is a systematic review aiming to investigate the role of JAK inhibitors in the treatment of CTCL, including their efficacy and safety. Out of 438 initially searched articles, we present 13 eligible ones. The overall response rate (ORR) in the treatment with JAK inhibitors in clinical trials was 11\u201335%, although different subtypes of CTCL showed different ORRs. Mycosis fungoides showed an ORR of 14\u201345%, while subcutaneous-panniculitis-like T-cell lymphoma (SPTCL) displayed an ORR ranging from 75% to 100%. Five cases were reported having a relapse\/incident of CTCL after using JAK inhibitors; of these, three cases were de novo CTCLs in patients under treatment with a JAK inhibitor due to refractory arthritis, and two cases were relapsed disease after graft-versus-host disease treatment following allo-SCT. In conclusion, using JAK inhibitors for CTCL treatment seems promising with acceptable side effects, especially in patients with SPTCL. Some biomarkers, like pS6, showed an association with better responses. Caution should be taken when treating patients with an underlying autoimmune disease and prior immunosuppression.<\/jats:p>","DOI":"10.3390\/cancers16050861","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T06:50:22Z","timestamp":1708498222000},"page":"861","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-6803","authenticated-orcid":false,"given":"Seyed Mohammad","family":"Vahabi","sequence":"first","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran 1461884513, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Bahramian","sequence":"additional","affiliation":[{"name":"School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Esmaeili","sequence":"additional","affiliation":[{"name":"School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717411, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3742-642X","authenticated-orcid":false,"given":"Bardia","family":"Danaei","sequence":"additional","affiliation":[{"name":"School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717411, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasamin","family":"Kalantari","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran 1461884513, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4394-8929","authenticated-orcid":false,"given":"Patrick","family":"Fazeli","sequence":"additional","affiliation":[{"name":"Independent Researcher, Agoura Hills, CA 91301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-1487","authenticated-orcid":false,"given":"Sara","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"School of Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Hajizadeh","sequence":"additional","affiliation":[{"name":"School of Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-9432","authenticated-orcid":false,"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Helios Klinikum Krefeld, 47805 Krefeld, Germany"},{"name":"Institute for Molecular Medicine, Medical School Hamburg, 20457 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifa","family":"Etesami","sequence":"additional","affiliation":[{"name":"Departments of Dermatology, Razi Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran 1983969411, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"ref_1","first-page":"1703","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_3","first-page":"e259","article-title":"Childhood mycosis fungoides: A clinicopathologic study of 30 cases from Iran","volume":"61","author":"Nasimi","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_5","first-page":"1229","article-title":"The international consensus classification of mature lymphoid neoplasms: A report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1590\/abd1806-4841.20187134","article-title":"Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides","volume":"93","author":"Amorim","year":"2018","journal-title":"Anais Bras. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","article-title":"A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome","volume":"49","author":"Benton","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and S\u00e9zary syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ajh.26299","article-title":"Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management","volume":"96","author":"Hristov","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-020-00809-w","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Updates and review of current therapy","volume":"22","author":"Kamijo","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_12","first-page":"537","article-title":"S2k-Guidelines\u2013Cutaneous lymphomas (ICD10 C82-C86): Update 2021","volume":"20","author":"Dippel","year":"2022","journal-title":"J. Der Dtsch. Dermatol. Ges."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): A propensity score matched controlled prospective study","volume":"401","author":"Mear","year":"2023","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2017.05.033","article-title":"Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition","volume":"451","author":"Groner","year":"2017","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"Anais Bras. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging Topical and Systemic JAK Inhibitors in Dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gallardo, F., and Pujol, R.M. (2022). Genetics Abnormalities with Clinical Impact in Primary Cutaneous Lymphomas. Cancers, 14.","DOI":"10.3390\/cancers14204972"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.2019004256","article-title":"Genetic and epigenetic insights into cutaneous T-cell lymphoma","volume":"139","author":"Tensen","year":"2022","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-D\u00edaz, N., Piris, M., Ortiz-Romero, P.L., and Vaqu\u00e9, J.P. (2021). Mycosis Fungoides and S\u00e9zary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. Cancers, 13.","DOI":"10.3390\/cancers13081931"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Luo, Y., Vermeer, M.H., de Haan, S., Kinderman, P., de Gruijl, F.R., van Hall, T., and Tensen, C.P. (2023). Socs1-knockout in skin-resident CD4(+) T cells in a protracted contact-allergic reaction results in an autonomous skin inflammation with features of early-stage mycosis fungoides. Biochem. Biophys. Rep., 35.","DOI":"10.1016\/j.bbrep.2023.101535"},{"key":"ref_22","first-page":"702","article-title":"Deregulation of JAK2 signaling underlies primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma","volume":"107","author":"Cats","year":"2022","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/ijd.15451","article-title":"Cell signaling in cutaneous T-cell lymphoma microenvironment: Promising targets for molecular-specific treatment","volume":"60","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1080\/09546634.2018.1546043","article-title":"JAK-inhibitors in dermatology: Current evidence and future applications","volume":"30","author":"Ciechanowicz","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17512433.2023.2193682","article-title":"JAK inhibitors in dermatology: The road travelled and path ahead, a narrative review","volume":"16","author":"Muddebihal","year":"2023","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Lastiri","year":"2023","journal-title":"Front. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Shawky, A.M., Almalki, F.A., Abdalla, A.N., Abdelazeem, A.H., and Gouda, A.M. (2022). A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051001"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1043254","DOI":"10.3389\/fonc.2022.1043254","article-title":"Advances in the understanding and treatment of Cutaneous T-cell Lymphoma","volume":"12","author":"Bakr","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjd.18098","article-title":"Advanced-stage mycosis fungoides: Role of the signal transducer and activator of transcription 3, nuclear factor-\u03baB and nuclear factor of activated T cells pathways","volume":"182","author":"Cereceda","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vadivel, C.K., Gluud, M., Torres-Rusillo, S., Boding, L., Willerslev-Olsen, A., Buus, T.B., Nielsen, T.K., Persson, J.L., Bonefeld, C.M., and Geisler, C. (2021). JAK3 is expressed in the nucleus of malignant T cells in cutaneous T cell lymphoma (CTCL). Cancers, 13.","DOI":"10.3390\/cancers13020280"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"key":"ref_36","first-page":"2435","article-title":"Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway","volume":"138","author":"Lee","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_37","first-page":"2828","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood-2018-99-119944","article-title":"The novel SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood-2019-125017","article-title":"Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2018-99-112123","article-title":"Durable responses observed with JAK inhibition in T-cell lymphomas","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/bloodadvances.2020001497","article-title":"Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis","volume":"4","author":"Fusaro","year":"2020","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jdcr.2022.10.010","article-title":"A case of erythrodermic mycosis fungoides responding to upadacitinib","volume":"30","author":"Castillo","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_44","first-page":"30","article-title":"A Case of Mycosis Fungoides Mimicking Atopic Dermatitis Treated with Upadacitinib","volume":"102","author":"Kook","year":"2022","journal-title":"Acta Derm.-Venereol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1080\/10428194.2022.2118537","article-title":"Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma","volume":"63","author":"Watson","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/ejh.13593","article-title":"Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series","volume":"106","author":"Hansen","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s13023-022-02575-4","article-title":"A retrospective study of 18 children with subcutaneous panniculitis-like T-cell lymphoma: Multidrug combination chemotherapy or immunomodulatory therapy?","volume":"17","author":"Duan","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bjh.18817","article-title":"Efficacy of ruxolitinib for HAVCR2 mutation-associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children","volume":"202","author":"Zhang","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1684\/ejd.2022.4238","article-title":"Lymphomatoid papulosis during upadacitinib treatment for rheumatoid arthritis","volume":"32","author":"Iinuma","year":"2022","journal-title":"Eur. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/DAD.0000000000002219","article-title":"A Case of Tofacitinib-Induced Lymphomatoid Papulosis With Ocular Involvement","volume":"44","author":"Steele","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ced\/llac124","article-title":"A case of S\u00e9zary syndrome in a patient during treatment with baricitinib for seronegative rheumatoid arthritis","volume":"48","author":"Saito","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_52","first-page":"e32","article-title":"Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib","volume":"38","author":"Cohen","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_53","first-page":"S34","article-title":"Real life data on advanced cutaneous T cell lymphoma patients treated with brentuximab vedotin: Results from a multicenter European EORTC study","volume":"119","author":"Papadavid","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e15858","DOI":"10.1111\/dth.15858","article-title":"Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series","volume":"35","author":"Amagai","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_56","first-page":"3290","article-title":"Targeting macrophages for enhancing CD47 blockade\u2013elicited lymphoma clearance and overcoming tumor-induced immunosuppression","volume":"139","author":"Cao","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(21)00271-4","article-title":"Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or S\u00e9zary syndrome: A multicentre, phase 1 study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40259-013-0040-7","article-title":"The arrival of JAK inhibitors: Advancing the treatment of immune and hematologic disorders","volume":"27","author":"Furumoto","year":"2013","journal-title":"BioDrugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: Part I. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","article-title":"Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yi, Y.W., You, K.S., Park, J.-S., Lee, S.-G., and Seong, Y.-S. (2021). Ribosomal protein S6: A potential therapeutic target against cancer?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010048"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/blood-2023-185543","article-title":"Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)","volume":"142","author":"Jin","year":"2023","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/bloodadvances.2021004562","article-title":"Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations","volume":"5","author":"Koh","year":"2021","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/1744666X.2022.2039630","article-title":"Safety of JAK inhibitors: Focus on cardiovascular and thromboembolic events","volume":"18","author":"Atzeni","year":"2022","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2022.2069562","article-title":"Emerging therapies for ulcerative colitis","volume":"18","author":"Hanzel","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","article-title":"Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis","volume":"160","author":"Ingrassia","year":"2023","journal-title":"JAMA Dermatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/861\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:23Z","timestamp":1760104943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16050861"],"URL":"https:\/\/doi.org\/10.3390\/cancers16050861","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}